Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q1 2022

Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.

Institution overview
Positions
29
−6 vs. Q4 2021
Portfolio value
$413.2M
−$34.1M (−7.6%) vs. Q4 2021
Filed
May 16, 2022
SEC
Holdings of Great Point Partners LLC in Q1 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
EXELExelixis, Inc.COM1,300,000$29.5M7.1%−450,000−25.7%ReducedHistory
XENEXenon Pharmaceuticals Inc.COM920,000$28.1M6.8%−30,000−3.2%ReducedHistory
TVTXTravere Therapeutics, Inc.COM1,010,000$26.0M6.3%+210,000+26.3%AddedHistory
BCYCBicycle Therapeutics PLCSPONSORED ADS550,592$24.2M5.8%+350,592+175.3%AddedHistory
JAZZJazz Pharmaceuticals plcSHS USD155,000$24.1M5.8%+155,000NewHistory
CYTKCytokinetics IncCOM NEW650,000$23.9M5.8%+300,000+85.7%AddedHistory
KDNYChinook Therapeutics, Inc.COM1,423,682$23.3M5.6%+1,033,641+265.0%AddedHistory
LKFTLakefront Biotherapeutics NVSPON ADR360,000$22.3M5.4%+60,000+20.0%AddedHistory
VRTXVertex Pharmaceuticals IncStock85,000$22.2M5.4%00.0%UnchangedHistory
PCVXVaxcyte, Inc.COM885,153$21.4M5.2%+385,153+77.0%AddedHistory
RLMDRelmada Therapeutics, Inc.COM790,000$21.3M5.2%+72,680+10.1%AddedHistory
ANABAnaptysbio, IncCOM700,000$17.3M4.2%+107,750+18.2%AddedHistory
PNTPOINT Biopharma Global Inc.COM2,060,000$16.4M4.0%+1,869,480+981.3%AddedHistory
ACRSAclaris Therapeutics, Inc.COM942,445$16.2M3.9%+142,445+17.8%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM874,197$12.9M3.1%+462,260+112.2%AddedHistory
RIGLRigel Pharmaceuticals IncCOM NEW4,000,000$12.0M2.9%−1,000,000−20.0%ReducedHistory
KNSAKiniksa Pharmaceuticals International, plcCOM CL A1,118,067$11.1M2.7%+581,329+108.3%AddedHistory
TCDATricida, Inc.COM1,250,000$10.3M2.5%−150,000−10.7%ReducedHistory
Avidity Biosciences, Inc.05370A108COM500,000$9.23M2.2%00.0%Unchanged–
SLNSilence Therapeutics plcADS444,443$8.44M2.0%00.0%UnchangedHistory
URGNUroGen Pharma Ltd.COM873,424$7.61M1.8%00.0%UnchangedHistory
Pieris Pharmaceuticals Inc720795103COM2,199,076$6.66M1.6%+649,076+41.9%Added–
ARDXArdelyx, Inc.COM4,761,905$5.09M1.2%+4,761,905NewHistory
VTYXVentyx Biosciences, Inc.COM336,334$4.56M1.1%+336,334NewHistory
ABOSAcumen Pharmaceuticals, Inc.COM928,282$3.63M0.9%+928,282NewHistory
DNTHDianthus Therapeutics, Inc.COM1,170,000$3.39M0.8%00.0%UnchangedHistory
CINCCinCor Pharma, Inc.COM79,670$1.40M0.3%+79,670NewHistory
PASGPassage BIO, Inc.COM113,900$353.0K0.1%−1,404,195−92.5%ReducedHistory
RFLRafael Holdings, Inc.COM CL B121,000$304.0K0.1%−164,714−57.6%ReducedHistory

Options (1)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Great Point Partners LLC in Q1 2022
SecurityClassPutsCalls
NKTRNektar TherapeuticsCOM–$539.0K

Sold out since Q4 2021 (11)

Positions held at the end of Q4 2021 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q4 2021
SecurityClassShares in Q4 2021Value in Q4 2021% of portfolio in Q4 2021History
ARNAArena Pharmaceuticals IncCOM NEW530,670$49.3M11.0%History
BCABBioAtla, Inc.COM864,300$17.0M3.8%History
MGNXMacrogenics IncCOM1,000,000$16.1M3.6%History
SRPTSarepta Therapeutics, Inc.COM145,405$13.1M2.9%History
RCKTRocket Pharmaceuticals, Inc.COM500,526$10.9M2.4%History
DYNDyne Therapeutics, Inc.COM845,000$10.0M2.2%History
PRQRProQR Therapeutics N.V.SHS EURO1,121,122$8.98M2.0%History
PYXSPyxis Oncology, Inc.COMMON STOCK400,000$4.39M1.0%History
SYRESpyre Therapeutics, Inc.COM910,251$4.32M1.0%History
ABUSArbutus Biopharma CorpCOM668,907$2.60M0.6%History
CABACabaletta Bio, Inc.COM472,433$1.79M0.4%History